Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. director and Chief Executive Officer Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026 in an underwritten public offering at a combined public offering price of $0.99 per share and warrant. The warrants are exercisable immediately at $1.10 per share and expire on August 14, 2031. Following these transactions, Jahr holds 151,515 common shares and 151,515 warrants directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 151,515 shares
Net Buy
2 txns
Insider
Jahr Robert Charles
Role
Chief Executive Officer
Bought
303,030 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants (right to buy) F2, F1 | 151,515 | -- | -- |
| Purchase | Common Stock F1 | 151,515 | -- | -- |
Holdings After Transaction:
Warrants (right to buy) — 151,515 shares (Direct);
Common Stock — 151,515 shares (Direct)
Footnotes (2)
- F1. On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.
- F2. The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031.
Key Figures
Common shares purchased: 151,515 shares
Warrants purchased: 151,515 warrants
Combined offering price: $0.99
+3 more
6 metrics
Common shares purchased
151,515 shares
Common stock acquired by CEO on August 14, 2026
Warrants purchased
151,515 warrants
Warrants acquired with common stock in underwritten public offering
Combined offering price
$0.99
Per share of common stock and accompanying warrant in the offering
Warrant exercise price
$1.10
Exercise price per share for the acquired warrants
Warrant expiration date
August 14, 2031
Five years from the date of issuance
Total net shares bought
303,030 securities
Sum of common shares and underlying warrant shares reported as net buy
Key Terms
underwritten public offering, accompanying warrants, combined public offering price, exercisable immediately
4 terms
underwritten public offering financial
"acquired 151,515 shares of common stock and accompanying warrants ... in the Issuer's underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
accompanying warrants financial
"shares of common stock and accompanying warrants to purchase 151,515 shares of common stock"
Securities called accompanying warrants are options issued together with another financing instrument—often bonds or preferred shares—that give the holder the right to buy common stock at a set price for a limited time. Think of them like detachable coupons included with a loan that can be redeemed later for stock; they matter to investors because they can dilute existing ownership if exercised and add potential upside tied to the issuer’s future share price.
combined public offering price financial
"for a combined public offering price of $0.99 per share of common stock and accompanying warrant"
exercisable immediately financial
"The warrants were exercisable immediately upon issuance and expire five years from the date of issuance"
FAQ
What did Outlook Therapeutics (OTLK) CEO Robert Charles Jahr buy on August 14, 2026?
Robert Charles Jahr bought 151,515 shares of common stock and 151,515 accompanying warrants of Outlook Therapeutics on August 14, 2026 in an underwritten public offering, as disclosed in the Form 4 filing.
At what price did the OTLK CEO purchase the common stock and warrants?
The CEO purchased the securities at a combined public offering price of $0.99 per share of common stock and accompanying warrant in the underwritten public offering, according to the Form 4 footnote.
What are the key terms of the warrants acquired by the OTLK CEO?
The acquired warrants are exercisable immediately at an exercise price of $1.10 per share and expire five years after issuance, on August 14, 2031, and relate to 151,515 underlying shares of common stock.
Were the OTLK CEO’s August 14, 2026 purchases under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and no footnote describes a trading plan, so the reported August 14, 2026 purchases are not identified as being made under a Rule 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
